



Lo real es lo que nos da sentido

- Más de **380.000¹** pacientes tratadas en más de **100 países¹**
- 7 años* de experiencia en vida real^{2,3}
- Eficacia y efectividad demostradas en ensayos clínicos y en vida real⁴⁻⁹ y el perfil de seguridad consistente y manejable sin toxicidades acumulativas o tardías tras 5 años de seguimiento^{3,9,10}



FICHA TÉCNICA DISPONIBLE AQUÍ
 Ibrance® es (f)comercializado en EEUU en el año 2015 y en España en el año 2017. 1. Real-world evidence supports effectiveness of first-line Ibrance® (palbociclib) combination therapy in HR+, HER2- metastatic breast cancer [Internet]. 2021. Disponible en: <https://www.pfizer.com/news/press-releases/press-release-detail/real-world-evidence-supports-effectiveness-first-line> [último acceso: 10/22]. 2. DeMichele, A., et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. *Breast Cancer Res.* 2021; 23:37-3. 3. Finn RS, et al. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. *Oncologist.* 2021; May;26(5):e749-e755-4. 4. Cristofani M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016; 17(4):425-439. 5. Rugo HS, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat.* 2019; 174(3):719-729. 6. Sans P, et al. Palbociclib in metastatic breast cancer: current evidence and real-life data. *Drugs Context.* 2019;8:212279. 7. Taylor-Stokes G, et al. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the RIS study. *Breast.* 2019;43:23-27. 8. Turner NC, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. *N Engl J Med.* 2018; 379(20):1926-1938. 9. Ficha técnica de Ibrance®. 10. Dieras V, et al. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. *J Natl Cancer Inst.* 2019; 111(4):419-430.